27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
PTC Therapeutics, Inc. (NASDAQ:PTCT) shares popped Thursday morning, following a note from Credit Suisse that said the stock could trade up by more than 500 percent..
The predicted activity will depend on corporate expenses and the company’s upcoming cystic fibrosis data. PTC is in Phase 3 for its Ataluren Confirmatory Trial in Cystic Fibrosis.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
“Risk/reward is very good due to low expectations,” the Credit Suisse note read. “Our near-term focus for shares is upcoming CF data in Q1 2017 readout where we think that investor expectations remain low.”
Related Link: Couldn't Make It To Leerink's Global Healthcare Conference? Here Are The Highlights From Day One
The U.S. Food and Drug Administration has granted ataluren orphan drug designation for treatment of both cystic fibrosis and Duchenne muscular dystrophy.
Shares of PTC were trading around $13.50 at time of publication, up more than 5.5 percent.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.